besifovir Report issue

Small molecule Experimental
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now
Besifovir (INN) is an investigational medication to treat hepatitis B virus (HBV) infection. It is a novel and potent acyclic nucleotide phosphonate with a similar chemical structure to adefovir and tenofovir.   Wikipedia

Chemistry

  • SMILES: Nc1ncc2ncn(CC3(OCP(=O)(O)O)CC3)c2n1
  • InChIKey: KDNSSKPZBDNJDF-UHFFFAOYSA-N
  • Mol. Mass: 299.23
  • ALogP: 0.09
  • ChEMBL Molecule:
    besifovir  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

((1-((2-amino-9h-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid di(pivaloyloxymethyl) ester | ((1-((2-amino-9h-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl | besifovir | lb80380 | lb-80380 | pmcdg dipivoxyl

Organizations (18)

Research & Development (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Hepatitis B

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Anesthesia (Phase 4)

Health (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 3)

Kidney Failure, Chronic (Phase 1)

Pharmacology (Phase 4)

Tenofovir (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 18

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue